AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Description: AcelRx Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct's pharmaceuticals report, “AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the AcelRx Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, AcelRx Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from AcelRx Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- AcelRx Pharmaceuticals, Inc. - Brief AcelRx Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of AcelRx Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of AcelRx Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the AcelRx Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate AcelRx Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of AcelRx Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the AcelRx Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with AcelRx Pharmaceuticals, Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of AcelRx Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Contents:

2
List of Tables 4
List of Figures 4
AcelRx Pharmaceuticals, Inc. Snapshot 5
AcelRx Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
AcelRx Pharmaceuticals, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
AcelRx Pharmaceuticals, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Combination Treatment Modalities 10
AcelRx Pharmaceuticals, Inc. – Pipeline Products Glance 11
AcelRx Pharmaceuticals, Inc. – Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
AcelRx Pharmaceuticals, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
AcelRx Pharmaceuticals, Inc. – Drug Profiles 13
ARX-01 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
ARX-02 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
ARX-04 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
sufentanil + triazolam 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AcelRx Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 21
AcelRx Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action 22
AcelRx Pharmaceuticals, Inc. – Recent Pipeline Updates 23
AcelRx Pharmaceuticals, Inc. – Locations And Subsidiaries 26
Head Office 26
AcelRx Pharmaceuticals, Inc., Recent Developments 27
AcelRx Pharmaceuticals, Inc.- Press Release 27
Nov 14, 2012: AcelRx Pharma’s Sufentanil NanoTab PCA System Achieves Primary End-Point In Phase III Comparative Study 27
Nov 05, 2012: AcelRx Pharma Doses First Patient In ARX-04 Phase II Clinical Study 27
Aug 23, 2012: AcelRx Pharma Initiates Third Phase III Clinical Trial For ARX-01 For Treatment Of Post-Operative Pain 28
Aug 01, 2012: AcelRx Pharma Receives Two Additional US Patents For Small-Volume Oral Transmucosal Dosage Forms 29
Apr 12, 2012: AcelRx Initiates Second Phase III Clinical Trial For ARX-01 For Treatment Of Acute Post-Operative Pain 30
Apr 11, 2012: AcelRx Pharma Receives Two Notices Of Allowance For Small-Volume Oral Transmucosal Dosage Forms 31
Mar 06, 2012: AcelRx Initiates Phase III Clinical Program For ARX-01 For Treatment Of Post-Operative Pain 31
Jan 31, 2012: AcelRx Provides Update On ARX-01 Phase III Program 32
Oct 30, 2009: AcelRx Announces Successful Completion Of End-of-Phase II Meeting On ARX-01 For Post-Operative Pain Management 33
Oct 22, 2009: AcelRx Announces Positive Results From Phase II Study Of ARX-03 For Procedural Sedation, Anxiolysis & Analgesia 34
Jul 22, 2009: AcelRx Announces Perfect Performance Of Handheld Component Of ARX-01 Sufentanil NanoTab PCA System In Phase II Study 35
Jun 29, 2009: AcelRx Announces Positive Phase II Results Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain 35
Apr 22, 2009: AcelRx Announces Initiation Of Phase II Trial For ARX-02 In Breakthrough Cancer Pain 36
Jan 12, 2009: AcelRx Pharmaceuticals Reports Positive Results From Phase I Clinical Trial Of ARX-03 In Treating Procedural Pain And Anxiety 37
Financial Deals Landscape 38
AcelRx Pharmaceuticals, Inc., Deals Summary 38
AcelRx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 39
Venture Financing 39
AcelRx Pharma Raises $8 Million In Venture Financing 39
AcelRx Pharma Secures $14.8 Million In Financing Round 40
AcelRx Pharma Secures $12 Million In Financing 42
AcelRx Pharma Secures $20.21 Million In Venture Financing 43
AcelRx Pharma Secures $19.79 Million In Series A Financing 45
Equity Offering 47
AcelRx Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For $6 Million 47
AcelRx Pharma Completes Private Placement Of Units For $10 Million 49
AcelRx Pharma Completes IPO Of $40 Million 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
AcelRx Pharmaceuticals, Inc., Key Information 5
AcelRx Pharmaceuticals, Inc., Key Facts 5
AcelRx Pharmaceuticals, Inc. – Pipeline by Indication, 2012 7
AcelRx Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 8
AcelRx Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 9
AcelRx Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012 10
AcelRx Pharmaceuticals, Inc. – Phase III, 2012 11
AcelRx Pharmaceuticals, Inc. – Phase II, 2012 12
AcelRx Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 21
AcelRx Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012 22
AcelRx Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012 23
AcelRx Pharmaceuticals, Inc., Deals Summary 38
AcelRx Pharma Raises $8 Million In Venture Financing 39
AcelRx Pharma Secures $14.8 Million In Financing Round 40
AcelRx Pharma Secures $12 Million In Financing 42
AcelRx Pharma Secures $20.21 Million In Venture Financing 43
AcelRx Pharma Secures $19.79 Million In Series A Financing 45
AcelRx Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For $6 Million 47
AcelRx Pharma Completes Private Placement Of Units For $10 Million 49
AcelRx Pharma Completes IPO Of $40 Million 51

List of Figures
AcelRx Pharmaceuticals, Inc. – Pipeline by Indication, 2012 7
AcelRx Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 8
AcelRx Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 9
AcelRx Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012 10
AcelRx Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 21
AcelRx Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012 22

Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Web Address: http://www.researchandmarkets.com/reports/2373045/
- Office Code: SCD2W4LL

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 4500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

- Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
- First Name: ___________________________  Last Name: ___________________________
- Email Address: * ___________________________
- Job Title: ___________________________
- Organisation: ___________________________
- Address: ___________________________
- City: ___________________________
- Postal / Zip Code: ___________________________
- Country: ___________________________
- Phone Number: ___________________________
- Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World